We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Aevi Genomic Medicine has received positive feedback from the United States Food and Drug Administration (FDA) on an improved version of the company's lead development molecule, AEVI-001, identified as AEVI-004.